Calista Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Out of Business

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Out of Business

Calista Therapeutics General Information

Description

Developer of proprietary peptide drugs intended for cystic fibrosis. The company discovers and develops novel therapeutics that modulate cellular transport and location, and activate membrane receptors, enabling medical professionals to provide improved treatments for people with cystic fibrosis.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 32 Riverside Drive
  • Lincoln, RI 02865
  • United States
+1 (401)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 32 Riverside Drive
  • Lincoln, RI 02865
  • United States
+1 (401)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calista Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 09-Aug-2025 Completed Out of Business
4. Grant 01-Feb-2021 Completed Pre-Clinical Trials
3. Grant 01-Jul-2014 Completed Startup
2. Grant 15-Sep-2013 $225K Completed Startup
1. Accelerator/Incubator 22-May-2013 Completed Startup
To view Calista Therapeutics’s complete valuation and funding history, request access »

Calista Therapeutics Patents

Calista Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210393516-A1 Solid implant formulation for drug delivery Inactive 14-Mar-2019
US-20240423906-A1 Solid implant formulation for drug delivery Pending 14-Mar-2019
CA-2908103-A1 Compositions and methods of use for cell targeted inhibitors of the cystic fibrosis transmembrane regulator associated ligand Inactive 02-Oct-2015
AU-2015234367-A1 Compositions and methods of use for cell targeted inhibitors of the cystic fibrosis transmembrane regulator associated ligand Inactive 01-Oct-2015
US-20170114093-A1 Methods of treatment and prevention of disease by arginine-rich compositions that induce cytoprotection and neuroprotection Inactive 29-May-2015 C07K7/06
To view Calista Therapeutics’s complete patent history, request access »

Calista Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calista Therapeutics FAQs

  • When was Calista Therapeutics founded?

    Calista Therapeutics was founded in 2012.

  • Where is Calista Therapeutics headquartered?

    Calista Therapeutics is headquartered in Lincoln, RI.

  • What is the size of Calista Therapeutics?

    Calista Therapeutics has 2 total employees.

  • What industry is Calista Therapeutics in?

    Calista Therapeutics’s primary industry is Drug Discovery.

  • Is Calista Therapeutics a private or public company?

    Calista Therapeutics is a Private company.

  • What is Calista Therapeutics’s current revenue?

    The current revenue for Calista Therapeutics is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process